Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
4.260
-0.230 (-5.12%)
At close: Dec 20, 2024, 4:00 PM
4.310
+0.050 (1.17%)
After-hours: Dec 20, 2024, 7:43 PM EST
Cardiff Oncology Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cardiff Oncology stock have an average target of 10.33, with a low estimate of 8.00 and a high estimate of 13. The average target predicts an increase of 142.49% from the current stock price of 4.26.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CRDF stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $7 → $10 | Buy | Maintains | $7 → $10 | +134.74% | Dec 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +205.16% | Nov 8, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +87.79% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +228.64% | May 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $14 | Strong Buy | Maintains | $12 → $14 | +228.64% | Mar 6, 2024 |
Financial Forecast
Revenue This Year
604.04K
from 488.00K
Increased by 23.78%
Revenue Next Year
328.44K
from 604.04K
Decreased by -45.63%
EPS This Year
-1.00
from -0.93
EPS Next Year
-0.94
from -1.00
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 785,400 | 1.1M | 420,000 | |||
| Avg | 604,044 | 328,440 | 135,997 | |||
| Low | 490,000 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 60.9% | 75.6% | 27.9% | |||
| Avg | 23.8% | -45.6% | -58.6% | |||
| Low | 0.4% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.98 | -0.74 | -0.89 | ||
| Avg | -1.00 | -0.94 | -1.16 | ||
| Low | -1.01 | -1.29 | -1.47 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.